Latest

M. ReckS. PetersG. MountziosN. Reguart

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

Learn more about the event

Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC

May 04 2026

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

INDUSTRY SYMPOSIUM

S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniN. FrostG. MountziosA. Dingemans

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

Best Practices in Managing Adverse Events with ADCs in NSCLC

} 18 min

N. Girard

From Our Annual Summit

ILCS Sessions

Nov132026

ILCS 2026

The International Lung Cancer Summit 2026

Learn more about the event

ILCS 2025

SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

ILCS 2025

Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

The ADC Revolution in Lung Cancer: New Targets, New Opportunities

} 27 min

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw

Expert Insights

Webinars

Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin

Dec 18 2025

Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard

Jul 10 2025

O. GautschiJ. NaidooN. Girard

Targeted Therapies in NSCLC

} 1h 30 min

IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde

Jun 25 2025

P. FordeJ. RemonS. Peters

Immunotherapies in NSCLC

} 1h 47 min

SCLC by Solange Peters, Giannis Mountzios, Jacob Sands

Jun 17 2025

G. MountziosJ. SandsS. Peters

SCLCImmunotherapies

Small Cell Lung Cancer

} 1h 35 min

The Reading Room

Articles & Research

Oct 03 2026

Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles

Oct 03 2026

KRAS inhibitors in NSCLC: modest survival gains, inevitable resistance and combinations in early trials

V. Noronha

Oct 02 2026

Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial

X. Le

Oct 02 2026

Advanced NSCLCBiomarkersImmunotherapies

High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC

B. Ricciuti

Oct 01 2026

B. RicciutiJ. RemonD. Planchard

Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study

RAS alterations drove resistance in about one in ten oncogene-driven lung cancers progressing on targeted therapy

Sep 30 2026

S. BerezowskaL. BubendorfP. Hofman

Advanced NSCLCSCLCADCs

Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis

Spread through air spaces predicted relapse after both lobectomy and segmentectomy in JCOG0802 stage IA NSCLC

Sep 28 2026

Resectable NSCLCImmunotherapies

AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1

M. ReckM. Hochmair

Sep 26 2026

Incidental thymic radiation dose was independently associated with metastasis and death in 1107 patients with NSCLC

B. Ricciuti

Sep 25 2026

Resectable NSCLCTargeted Therapies

Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma

S. Saw

Sep 23 2026

CONGRESS

Zidesamtinib produced responses in 94% of ROS1 TKI-naive patients in ARROS-1

Sep 19 2026

Resectable NSCLC

Spread through air spaces carried an HR of 2.32 for DFS in stage 1 lung adenocarcinoma

S. Saw

Sep 18 2026

INDUSTRY NEWS

Grade 3 adverse events on the FLAURA2 combination fell from 43% during induction to 14% on osimertinib alone

First-line trastuzumab deruxtecan extended median PFS to 14.3 months in HER2-mutant NSCLC

Sep 16 2026

CONGRESS

SCLCTargeted Therapies

Tam-Peli extended median OS to 13.3 months in relapsed SCLC, against 9.4 months with topotecan

Sep 15 2026

CONGRESS

HARMONi-2: ivonescimab extends overall survival over pembrolizumab in China

Industry Sponsored

Featured Sessions

Jul 20 2026

M. ReckS. PetersG. MountziosN. Reguart

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

Learn more about the event

May 04 2026

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.